Journal of Clinical Endocrinology & Metabolism, Vol 55, 1124-1130, Copyright © 1982 by Endocrine Society

ARTICLES

Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women

C Christiansen, MS Christensen, NE Larsen and IB Transbol

Dose-response relationships of estrogen (E) on indices of calcium balance and bone activity were studied in normal early postmenopausal women. Calcium balance was estimated by changes in forearm bone mineral content, measured by photon absorptiometry. Bone activity was estimated by serum alkaline phosphatases (S-aPh), indicating bone formation, and by fasting urinary excretion of hydroxyproline (U-HyPro) and calcium (U- Ca), indicating bone resorption. A total of 92 female volunteers were randomized to 12 months' treatment with placebo or one of three different doses (high, medium, or low) of natural estrogens (17 beta- estradiol and estriol, 4/2, 2/1, and 1/0.5 mg, respectively), sequentially combined with the same dose (1 mg) of norethisterone acetate for 10 of the 28 cycle days. The trial was completed by 79 women. Bone mineral content declined by 2% (P less than 0.001) in the placebo group, remained constant in the low hormone group and increased by 0.8% (P less than 0.05) and 1.5% (P less than 0.01), respectively, in the medium and high hormone groups. S-aPh decreased gradually and equally by 20-25% in the three hormone groups and U-HyPro and U-Ca decreased by 30-40% during 1-yr hormone treatment, irrespective of dose. The decrease in these three indices occurred practically without exceptions. Compared to the values found in 48 normal premenopausal women the untreated postmenopausal women had increased values of S-aPh (P less than 0.001), U-HyPro (P less than 0.01), and U-Ca (P less than 0.001), and no pretreatment values were below the normal premenopausal range. After treatment the mean values of S-aPh and U-HyPro were slightly lower than the premenopausal mean values (P less than 0.01). These data strongly support the major importance of E deficiency for early postmenopausal bone loss, which is prevented by even a small substitution dose of E.

This article has been cited by other articles:

				F Labrie Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr. Relat. Cancer, June 1, 2006; 13(2): 335 - 355. [Abstract] [Full Text] [PDF]

				F Labrie, V Luu-The, A Belanger, S-X Lin, J Simard, G Pelletier, and C Labrie Is dehydroepiandrosterone a hormone? J. Endocrinol., November 1, 2005; 187(2): 169 - 196. [Abstract] [Full Text] [PDF]

				F. Labrie, M. El-Alfy, L. Berger, C. Labrie, C. Martel, A. Belanger, B. Candas, and G. Pelletier The Combination of a Novel Selective Estrogen Receptor Modulator with an Estrogen Protects the Mammary Gland and Uterus in a Rodent Model: The Future of Postmenopausal Women's Health? Endocrinology, November 1, 2003; 144(11): 4700 - 4706. [Abstract] [Full Text] [PDF]

				K. E. McDougall, M. J. Perry, R. L. Gibson, S. M. Colley, K. S. Korach, and J. H. Tobias Estrogen Receptor-{alpha} Dependency of Estrogen's Stimulatory Action on Cancellous Bone Formation in Male Mice Endocrinology, May 1, 2003; 144(5): 1994 - 1999. [Abstract] [Full Text] [PDF]

				F. Labrie, V. Luu-The, C. Labrie, A. Belanger, J. Simard, S.-X. Lin, and G. Pelletier Endocrine and Intracrine Sources of Androgens in Women: Inhibition of Breast Cancer and Other Roles of Androgens and Their Precursor Dehydroepiandrosterone Endocr. Rev., April 1, 2003; 24(2): 152 - 182. [Abstract] [Full Text] [PDF]

				K. E. McDougall, M. J. Perry, R. L. Gibson, J. M. Bright, S. M. Colley, J. B. Hodgin, O. Smithies, and J. H. Tobias Estrogen-induced osteogenesis in intact female mice lacking ERbeta Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E817 - E823. [Abstract] [Full Text] [PDF]

				J. H. Tobias, S. Clarke, K. Mitchell, S. Robins, H. Amer, and W. D. Fraser Analysis of the Contribution of Dydrogesterone to Bone Turnover Changes in Postmenopausal Women Commencing Hormone Replacement Therapy J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1194 - 1198. [Abstract] [Full Text]

				M. J. Perry, A. Samuels, D. Bird, and J. H. Tobias Effects of high-dose estrogen on murine hematopoietic bone marrow precede those on osteogenesis Am J Physiol Endocrinol Metab, November 1, 2000; 279(5): E1159 - E1165. [Abstract] [Full Text] [PDF]

				R. Brommage, C. E. Hotchkiss, C. J. Lees, M. W. Stancill, J. M. Hock, and C. P. Jerome Daily Treatment with Human Recombinant Parathyroid Hormone-(1-34), LY333334, for 1 Year Increases Bone Mass in Ovariectomized Monkeys J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3757 - 3763. [Abstract] [Full Text] [PDF]

				P. Moghetti, R. Castello, N. Zamberlan, M. Rossini, D. Gatti, C. Negri, F. Tosi, M. Muggeo, and S. Adami Spironolactone, But Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1250 - 1254. [Abstract] [Full Text]

				C. K. Lea, U. Sarma, and A. M. Flanagan Macrophage Colony Stimulating-Factor Transcripts Are Differentially Regulated in Rat Bone-Marrow by Gender Hormones Endocrinology, January 1, 1999; 140(1): 273 - 279. [Abstract] [Full Text]

				C. K. Lea and A. M. Flanagan Physiological plasma levels of androgens reduce bone loss in the ovariectomized rat Am J Physiol Endocrinol Metab, February 1, 1998; 274(2): E328 - E335. [Abstract] [Full Text] [PDF]

				F. Labrie, P. Diamond, L. Cusan, J.-L. Gomez, A. Belanger, and B. Candas Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal Women J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3498 - 3505. [Abstract] [Full Text] [PDF]

				P. E. Belchetz Hormonal Treatment of Postmenopausal Women N. Engl. J. Med., April 14, 1994; 330(15): 1062 - 1071. [Full Text]